Overview of Giant Cell Arteritis (GCA)

Overview of Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA) is a chronic inflammatory disorder that primarily targets large and medium-sized arteries, especially those in the head such as the temporal arteries. The condition becomes complicated when inflammation leads to serious issues such as vision impairment, stroke, or vascular damage. GCA typically affects individuals over the age of 50 and is frequently linked to polymyalgia rheumatica. Common symptoms include persistent headaches, tenderness of the scalp, jaw pain during chewing, and general fatigue. In advanced cases, it may result in sudden or permanent vision loss due to compromised blood flow to the optic nerve.

Treatment generally involves high-dose corticosteroids (e.g., prednisone) to rapidly reduce inflammation and avert serious complications. Early intervention is critical to preserving vision and preventing strokes. If steroid therapy is insufficient or causes side effects, immunosuppressants may be introduced. Long-term care involves routine monitoring to tailor treatments and mitigate side effects. Prompt diagnosis and immediate therapy are vital to controlling disease progression and enhancing patient outcomes.

Get the facts at a glance—view our new infographic

https://www.delveinsight.com/infographics/giant-cell-arteritis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr 

Giant Cell Arteritis Epidemiological Segmentation (2020–2034, 7MM)

• Diagnosed Prevalent Cases

• Region-Specific Data

• Subtype-Based Classification

• Gender-Based Distribution

• Age Group-Specific Analysis

• Symptom-Based Segmentation

• Total Number of Treated Cases
  
  

Giant Cell Arteritis Epidemiology

• Total prevalent cases in the 7MM are approximately 454,000.

• The U.S. represents 54% of diagnosed cases, the highest share among the 7MM.

• Cranial GCA is more common than extra-cranial variants in the U.S.

• The 80–89 age group accounts for the largest number of cases.

Giant Cell Arteritis Market Overview

• Market Size (2023, 7MM): Approximately USD 960 million
  
  

Get the data. Get the insights. Get the report

Market Growth Drivers

• Enhanced diagnostic and treatment protocols have improved identification and management.

• New disease-modifying therapies show potential for superior outcomes compared to symptom-only treatments.

• Biosimilar introductions promise lower costs and increased accessibility.

• Rising patient demand for effective options is accelerating innovation.

Market Barriers

• A limited understanding of the underlying disease mechanisms complicates therapy development.

• High treatment costs, especially for complex cases, add financial burden.

• Regulatory hurdles and reimbursement policies can delay access to newer therapies.

• The complex nature of GCA makes both diagnosis and treatment more challenging.

Simplified, visualized, and ready for you— See the infographic

Emerging Therapies for Giant Cell Arteritis

• RINVOQ

• COSENTYX

• TREMFYA

• Additional candidates in development
  
  

Key Companies in the GCA Market

• AbbVie

• Novartis Pharmaceuticals

• Janssen (Johnson & Johnson)

• And others

See the bigger picture—get the full report

https://www.delveinsight.com/report-store/giant-cell-arteritis-market?utm_source=infographics&utm_medium=promotion&utm_campaign=akpr